As glutaminase inhibitors have recently become clinically available for a variety of cancers and chronic conditions [52,53,54,55], study findings encourage further exploration of these inhibitors as potential therapies targeting metabolic flexibility, including glucose metabolism, in breast cancer. This evidence concerns the gene GLS and breast carcinoma.